Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotersen Open-Label Extension in FAP
NCT02175004Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Sep 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 9
01
Overview
A Phase 3 trial of inotersen in familial amyloid polyneuropathy (FAP), sponsored by Ionis Pharmaceuticals. Started Jun 2014; status: completed.
02
Drugs
inotersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on NCT02175004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175004.